

Targeting both GD2 and B7-H3 using bispecific antibody improves tumor selectivity for GD2-positive tumors

Zachary T. Rosenkrans^{1,2}, Amy K. Erbe^{2,3}, Nathan B. Clemons¹, Arika S. Feils, Yadira Medina-Guevara¹, Justin J. Jeffery², Todd E. Barnhart¹, Jonathan W. Engle^{1,2}, Paul M. Sondel^{2,3,4}, Reinier Hernandez^{1,2}*

¹Departments of Medical Physics and Radiology, University of Wisconsin-Madison, Madison, Wisconsin, USA

²University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin

³Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin

⁴Department of Pediatrics, University of Wisconsin-Madison, Madison, Wisconsin

Running title: Bispecific antibodies improve selectivity for GD2-positive tumors

*** Corresponding author:** Reinier Hernandez, Ph.D.
University of Wisconsin-Madison
Departments of Medical Physics and Radiology
1111 Highland Ave., Room 7137
Madison, WI 53705
Email: Hernandez6@wisc.edu

Abstract

Objectives:

Disialoganglioside 2 (GD2), overexpressed by cancers such as melanoma and neuroblastoma, is a tumor antigen for targeted therapy. The delivery of conventional IgG antibody technologies targeting GD2 is limited clinically by its co-expression on nerves that contributes to toxicity presenting as severe neuropathic pain. To improve the tumor selectivity of current GD2-targeting approaches, a next-generation bispecific antibody targeting GD2 and B7-H3 (CD276) was generated.

Methods:

Differential expression of human B7-H3 (hB7-H3) was transduced into GD2⁺ B78 murine melanoma cells and confirmed by flow cytometry. We assessed the avidity and selectivity of our GD2-B7-H3 targeting bispecific antibodies (INV34-6, INV33-2, and INV36-6) towards GD2⁺/hB7-H3⁻ B78 cells relative to GD2⁺/hB7-H3⁺ B78 cells using flow cytometry and competition binding assays, comparing results an anti-GD2 antibody (dinutuximab, DINU). The bispecific antibodies, DINU, and a non-targeted bispecific control (bsAb CTRL) were conjugated with deferoxamine for radiolabeling with Zr-89 ($t_{1/2} = 78.4$ h). Using positron emission tomography (PET) studies, we evaluated the in vivo avidity and selectivity of the GD2-B7-H3 targeting bispecific compared to bsAb CTRL and DINU using GD2⁺/hB7-H3⁺ and GD2⁺/hB7-H3⁻ B78 tumor models.

Results:

Flow cytometry and competition binding assays showed that INV34-6 bound with high avidity to GD2⁺/hB7-H3⁺ B78 cells with high avidity but not GD2⁺/hB7-H3⁻ B78 cells. In comparison, no selectivity between cell types was observed for DINU. PET in mice bearing the GD2⁺/hB7-H3⁻ and GD2⁺/hB7-H3⁺ B78 murine tumor showed similar biodistribution in normal tissues for [⁸⁹Zr]Zr-Df-INV34-6, [⁸⁹Zr]Zr-Df-bsAb CTRL, and [⁸⁹Zr]Zr-Df-DINU. Importantly, [⁸⁹Zr]Zr-Df-INV34-6 tumor uptake was selective to GD2⁺/hB7-H3⁺ B78 over GD2⁺/hB7-H3⁻ B78 tumors, and substantially higher to GD2⁺/hB7-H3⁺ B78 than the non-targeted [⁸⁹Zr]Zr-Df-bsAb CTRL control. [⁸⁹Zr]Zr-Df-DINU displayed similar uptake in both GD2⁺ tumor models, with uptake comparable to [⁸⁹Zr]Zr-Df-INV34-6 in the GD2⁺/hB7-H3⁺ B78 model.

Conclusion:

The GD2-B7-H3 targeting bispecific antibodies successfully improved selectivity to cells expressing both antigens. This approach should address the severe toxicities associated with GD2-targeting therapies by reducing off-tumor GD2 binding in nerves. Continued improvements in bispecific antibody technologies will continue to transform the therapeutic biologics landscape.

Keywords: bispecific, antibodies, GD2, B7-H3, positron emission tomography, imaging, melanoma, neuroblastoma, cancer

Introduction

Antibodies have been developed as immunotherapies of cancer by targeting disialoganglioside 2 (GD2), which is highly expressed on the surface of solid tumors such as neuroblastomas or melanomas.[1-3] Patients treated with anti-GD2 immunotherapy (dinutuximab, DINU) experience neuropathic pain arising from GD2 expression on peripheral nerve fibers.[4] The pain caused by anti-GD2 immunotherapy is ubiquitous across patients, can be debilitating, and narrows the therapeutic index.[5, 6] B7-H3 (CD276), an immune checkpoint antigen with limited expression on normal tissues such as liver and some immune cells, is highly expressed on many tumors, and is not expressed on nerves.[7-9] As such, immunotherapies targeting B7-H3 have been well tolerated with some anti-tumor activity in clinical trials.[10, 11] Thus, improving cancer cell selectivity by requiring co-expression of B7-H3 together with GD2 may potentially mitigate the agonizing pain induced by GD2-directed monoclonal antibodies.

Therapeutic immunoglobulin G (IgG) antibodies are emerging as the predominant treatment modality due to their pharmacokinetic properties, high specificity, and effector-driving function.[12] Advances in protein engineering techniques have facilitated the development of bispecific antibodies (bsAbs) that target two antigens or epitopes. The introduction of bsAbs has transformed the biological drug landscape, presenting a novel class of agents with therapeutic or diagnostic potential beyond the capabilities of monospecific IgG counterparts. The innovation of bsAbs permits novel strategies through additional control of avidity, specificity, biodistribution, and therapeutic mechanism of action. The emergence of bsAbs has spurred extensive clinical investigation, leading to successful regulatory approval of several.[13, 14]

We aim to improve the precision of antibody targeting toward GD2-positive tumors using a bsAb design that targets both GD2 and B7-H3 antigens. Our next generation approach

leverages a requirement of GD2 and B7-H3 co-expression to enhance cancer cell selectivity, minimizing binding and side effects associated with anti-GD2 mAb binding to GD2 expressed by nerves. Through positron emission tomography (PET), we evaluated the avidity and selectivity of GD2/B7-H3 bsAbs *in vivo*. By requiring the simultaneous presence of the GD2 and B7-H3 on the same cell, we anticipate an improved antibody agent that selectively targets tumor that co-express GD2 and B7-H3 but not to nerves that express GD2 but not B7-H3.

Materials and methods

Antibody conjugation for PET

Antibodies used in this study were kindly supplied by Invenra Inc (Madison, WI). p-SCN-Bn-Deferoxamine (Df) from purchased from Macrocyclics (Plano, Tx) was conjugated to antibodies for PET imaging. Using isothiocyanate chemistry, Df was dissolved in anhydrous DMSO and conjugated antibodies in PBS pH adjusted to 8.5-9 at a molar ratio of 5:1 (Df:antibody). Using end over end rotation, the reactions were conducted for 2-4 h at room temperature. Df conjugated antibodies were purified using a Cytiva (Marlborough, MA) PD-10 size exclusion chromatography column

Antibody radiolabeling

The UW-Madison Cyclotron Group produced [^{89}Zr]Zr-oxalate using the $^{\text{nat}}\text{Y}(p,n)^{89}\text{Zr}$ reaction on a PETtrace cyclotron (GE Healthcare [Madison, WI]). Zr-89 was used to radiolabel Df conjugated antibodies. For radiolabeling, Df conjugated antibodies were added to Zr-89 (100 ug per 37 MBq [1 mCi]) in 1 M HEPES buffer. Typical reactions utilized 1-2 mCi (37-74 MBq) of Zr-89. Radiolabeling reactions were performed at 37°C for 1 h and purified using a PD-10 size exclusion chromatography column (Cytiva). Instant thin layer chromatography (iTLC) was used to determine the radiolabeling efficiency.

Animal studies

All animal studies were conducted on a protocol approved by the Institutional Animal Care and Use Committee at the UW-Madison. Female or male C57BL/6 were purchased from Taconic and housed at the UW-Madison.

B78 tumor model

To establish B78 tumor allografts, mice were subcutaneously injected with 2×10^6 B78 cells engineered with differential GD2 and B7-H3 expression (GD2⁺/hB7-H3⁻ or GD2⁺/hB7-H3⁺). GD2⁺/hB7-H3⁻ B78 cells were established by CRISPR Cas9 knockout of endogenous murine B7-H3 in the GD2⁺ B78 parental cell line. GD2⁺/hB7-H3⁺ B78 cells were established by lentivirus transduction of hB7-H3. Imaging studies utilized GD2⁺/hB7-H3⁺ B78 and or GD2⁺/hB7-H3⁻ tumors implanted on the lower right flank of mice.

PET/CT imaging studies

Following intravenous injection of approximately 3.7 MBq – 7.4 MBq (100 μ Ci – 200 μ Ci) of radiotracer, PET or PET/CT were acquired using an Inveon μ PET/CT. CT images were captured using the following parameters: 80 kV, 900 μ A, resolution of 105 μ m. PET/CT images were acquired at 3 h, 24 h, 48 h, or 72 h post injection and reconstructed using an OSEM3D/MAP algorithm. Volume of interest (VOI) quantification of the collected images was performed in the Inveon Research Workstation. VOI quantified tissues included the blood, liver, spleen, tumor, kidney, muscle, and bone, reported in percent injected activity per cubic centimeter of tissue (%IA/cc). Ex vivo quantification of the injected mice was performed following the final imaging time point by harvesting tissues. A Wizard 2 (Perkin Elmer [Waltham, MA]) or Hidex AMG (Hidex [Turku, Finland]) gamma counter was used to quantify radioactivity. Quantification of

the ex vivo biodistribution data was reported in percent injected activity per gram of tissue (%IA/g).

Statistical Analysis

Statistical analysis was performed by two-tailed unpaired Student's *t* tests or one-way ANOVA. NS, non-significant * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.

Results

Designing a bispecific antibody platform targeting GD2 and B7-H3 using a bispecific antibody approach

Bispecific antibodies targeting GD2 and B7-H3 were prepared (**Fig. 1A**) in an IgG like format using the “knob-in-hole” mutations in the heavy chain constant region three [15, 16] with one arm containing a B7-H3 binding domain and one arm containing a GD2 binding domain. The selectivity of the bispecific antibody was designed by targeting B7-H3 with high-medium affinity and GD2 with low affinity in their respective Fab variable regions. We anticipated that the combination of these affinities should generate an bispecific antibodies that selectively target GD2⁺/hB7-H3⁺ cells with high avidity (**Fig. 1B**).

Screening in vitro avidity and selectivity for the bispecific GD2/hB7-H3 targeting antibody

The avidity and selectivity of the GD2/hB7-H3 targeting bispecific antibodies were screened using flow cytometry (**Fig. 2A**). Using GD2⁺ B78 cells that express the human variant of B7-H3 (hB7-H3), bispecific antibody INV34-6 bound with high avidity when both antigens were present on the cells ($EC_{50} = 3.1$ nM). In comparison, negligible binding of INV34-6 to B78 cells expressing GD2 only (simulating nerve) was observed ($EC > 100$ nM). As shown in **Fig. 2B**, we then evaluated DINU binding and found that DINU bound with high and comparable affinity to GD2⁺/hB7-H3⁻ ($EC_{50} = 13.5$ nM) or GD2⁺/hB7-H3⁺ ($EC_{50} = 29.9$ nM) B78 cells.

Similar binding selectivity and avidity was observed for another bispecific antibody (INV36-6) using the B78 cells expressing both antigens ($EC_{50} = 1$ nM) or only GD2 ($EC_{50} > 100$ nM) (**Fig. S1**). Additional evaluation of bispecific antibody binding properties was conducted using competitive radioactive binding assays (**Fig. 2C-D**). For GD2⁺/hB7-H3⁻ B78 cells, no displacement of the radioactive probe was observed for INV34-6 ($IC_{50} > 333$ nM). However, binding was observed when INV34-6 was incubated with GD2⁺/hB7-H3⁺ B78 cells (IC_{50} of 49.8 ± 12.4 nM). Other bispecific antibodies targeting GD2 and B7-H3 were shown to have comparable binding properties (**Fig. S2**). No selectivity was observed for DINU, which bound to GD2⁺/hB7-H3⁺ B78 cells and GD2⁺/hB7-H3⁻ B78 cells with comparable affinities ($IC_{50} = 33.9 \pm 15.4$ nM and $IC_{50} = 49.8 \pm 12.4$ nM, respectively).

Evaluating *in vivo* targeting using PET

We then investigated the *in vivo* targeting of INV34-6 radiolabeled with ⁸⁹Zr ($t_{1/2} = 74.2$ h) in mice bearing GD2⁺/hB7-H3⁺ B78 tumors using PET. A non-targeted bispecific control antibody (bsAb CTRL) evaluated non-specific uptake contributions of the bispecific platform. Antibodies were conjugated and efficiently radiolabeled with ⁸⁹Zr, as shown by the radiochemical yield of $94.3 \pm 1.6\%$ ($n=4$; **Fig. S3**) for [⁸⁹Zr]Zr-Df-INV34-6. After conjugation, radiolabeling, and purification, PET images were acquired ([⁸⁹Zr]Zr-Df-INV34-6 or [⁸⁹Zr]Zr-Df-bsAb CTRL) in GD2⁺/hB7-H3⁺ tumor bearing mice (**Fig. 3A**; [⁸⁹Zr]Zr-Df-INV33-2 or [⁸⁹Zr]Zr-Df-INV36-6 in **Fig. S4**; **Tables S1-S2**). As shown in the maximum intensity projection (MIP) images, tumors can clearly be delineated using [⁸⁹Zr]Zr-Df-INV34-6 as soon as 24 h post-injection (p.i.), whereas minimal tumor uptake was noted for non-specific [⁸⁹Zr]Zr-Df-bsAb CTRL. The differences in the tumor and normal tissue uptake for [⁸⁹Zr]Zr-Df-INV34-6 and [⁸⁹Zr]Zr-Df- bsAb CTRL were quantified using volume of interest (VOI) analysis (**Fig. 3B**).

Significantly higher tumor uptake for [^{89}Zr]Zr-Df-INV34-6 was first observed at 24 h p.i. (16.0 ± 1.0 %IA/cc vs. 7.4 ± 1.4 %IA/cc; $p = 0.00095$) compared to [^{89}Zr]Zr-Df-bsAb CTRL (7.4 ± 1.4 %IA/cc). The tumor uptake for [^{89}Zr]Zr-Df-INV34-6 peaked at 48 h p.i. (19.3 ± 0.7 %IA/cc) and then plateaued at 72 h p.i. (18.2 ± 1 %IA/cc), which remained significantly higher than [^{89}Zr]Zr-Df-bsAb CTRL at both timepoints (48 h: 6.9 ± 0.9 %IA/cc, $p < 0.001$; 72 h: 6.8 ± 1 %IA/cc, $p < 0.001$). The *in vivo* clearance of [^{89}Zr]Zr-Df-INV34-6 and [^{89}Zr]Zr-Df-bsAb CTRL from the blood was comparable over the PET study, with half-lives calculated using a one-phase exponential decay model to be 41.1 ± 2.7 h for [^{89}Zr]Zr-Df-INV34-6 and 55.2 ± 27.4 h for [^{89}Zr]Zr-Df-bsAb CTRL ($p=0.42$). In the other normal tissues of interest (blood, liver, spleen, kidney, muscle), the uptake of [^{89}Zr]Zr-Df-INV34-6 and [^{89}Zr]Zr-Df-bsAb CTRL was comparable at all timepoints. Notably, higher uptake of [^{89}Zr]Zr-Df-bsAb CTRL in the liver was observed albeit not significant. PET with other bispecific antibodies, [^{89}Zr]Zr-Df-INV33-2 or [^{89}Zr]Zr-Df-INV36-6, showed similar tumor and normal tissue uptake as [^{89}Zr]Zr-Df-INV34-6 (**Fig. S5**), demonstrating the versatility of the bispecific platform.

Following the 72 h terminal imaging timepoint, the mice were euthanized, and the major tissues of interest were collected for *ex vivo* quantification (**Fig. 3C: Table S3**). The enhanced avidity of [^{89}Zr]Zr-Df-INV34-6 was further demonstrated by significantly higher tumor uptake (19.1 ± 0.8 %IA/g) compared to [^{89}Zr]Zr-Df-bsAb CTRL (6.1 ± 0.3 %IA/g, $p < 0.001$). Otherwise, the sole noteworthy difference in tissue uptake was observed in the bone, which was significantly higher ($p = 0.003$) for [^{89}Zr]Zr-Df-INV34-6 (11.7 ± 2.4 %IA/g) compared to [^{89}Zr]Zr-Df-bsAb CTRL (2.9 ± 0.4 %IA/g). No notable differences in the *ex vivo* quantification of the tumor uptake was found between the other GD2 and B7-H3 targeting bispecific antibodies

of interest (**Fig. S6**). Overall, the biodistribution study corroborated the VOI analysis and demonstrated remarkable *in vivo* avidity toward GD2⁺/hB7-H3⁺ tumors.

Evaluating *in vivo* selectivity using PET/CT

The selectivity of INV34-6 towards GD2⁺/hB7-H3⁺ cells was then compared to DINU. As such, we used PET to evaluate uptake of [⁸⁹Zr]Zr-Df-INV34-6 and [⁸⁹Zr]Zr-Df-DINU in either GD2⁺/hB7-H3⁺ or GD2⁺/hB7-H3⁻ B78 tumor models. Representative MIP PET images of [⁸⁹Zr]Zr-Df-INV34-6 and [⁸⁹Zr]Zr-Df-DINU in GD2⁺/hB7-H3⁺ B78 tumors and GD2⁺/hB7-H3⁻ B78 tumors are shown in **Fig. 4**. VOI quantification of [⁸⁹Zr]Zr-Df-INV34-6 and [⁸⁹Zr]Zr-Df-DINU in mice bearing GD2⁺/hB7-H3⁺ or GD2⁺/hB7-H3⁻ B78 tumors showed similar biodistribution in normal tissues (**Fig. 5a-f; Table S4-S9**). Importantly, VOI quantification (**Fig. 5g; Table S10**) of [⁸⁹Zr]Zr-Df-INV34-6 showed selectivity toward GD2⁺/hB7-H3⁺ B78 tumors compared to GD2⁺/hB7-H3⁻ B78 tumors, with increased relative tumor uptake at 48 h p.i. and 72 h p.i. (10.8 ± 2.4 %IA/cc vs. 7.3 ± 1.5 %IA/cc and 12.4 ± 1.9 %IA/cc vs. 7.7 ± 1.4 %IA/cc, respectively). The peak tumor uptake of [⁸⁹Zr]Zr-Df-INV34-6 in GD2⁺/hB7-H3⁺ B78 tumors occurred at 72 h p.i.. In comparison, no significant difference in tumor uptake of [⁸⁹Zr]Zr-Df-DINU was observed in GD2⁺/hB7-H3⁺ vs GD2⁺/hB7-H3⁻ B78 tumors. Furthermore, no significant differences in tumor uptake for [⁸⁹Zr]Zr-Df-INV34-6 and [⁸⁹Zr]Zr-Df-DINU in GD2⁺/hB7-H3⁺ B78 tumors were found at any timepoint. *Ex vivo* tissue quantification at 72 h p.i. further confirmed increased ($p = 0.003$) uptake of [⁸⁹Zr]Zr-Df-INV34-6 in GD2⁺/hB7-H3⁺ B78 tumors (23.0 ± 2.4 %IA/g) compared to GD2⁺/hB7-H3⁻ B78 tumors (12.9 ± 1.4 %IA/g) (**Fig. 5h; Table S11**), while no significant difference was noted between the uptake of these antibodies in normal tissues (**Fig. S7**). No difference in [⁸⁹Zr]Zr-Df-DINU tumor uptake was observed in GD2⁺/hB7-H3⁻ B78 (20.6 ± 3.4 %IA/g) and GD2⁺/hB7-H3⁺ B78 (21.1 ± 2.3 %IA/g) models.

Moreover, no uptake difference was found between [^{89}Zr]Zr-Df-DINU and [^{89}Zr]Zr-Df-INV34-6 in GD2⁺/hB7-H3⁺ B78 tumors.

Discussion

Bispecific antibodies have been proposed as a next generation therapeutic approach for targeted cancer treatment. While monoclonal antibodies are typically designed to target a single epitope on an antigen of interest, bispecific antibodies are engineered to target two separate antigen or epitopes. This dual-targeting approach enables more precise and potent antibody therapies against cancer cells while sparing undesired toxicities and potentially overcoming resistance mechanisms. Although bispecific antibodies are commonly investigated as cancer treatment, they are also assessed as treatments in autoimmune diseases and infectious diseases, among others.[17] The evolving landscape of bispecific antibodies in biopharmaceuticals underscores their importance as innovative tools that can revolutionize the therapeutic arsenal, providing novel avenues for personalized medicine and improving patient outcomes.

Antibody therapeutics targeting GD2 have been investigated in preclinically and clinically, becoming part of the standard of care for children with high-risk neuroblastoma[5, 18]. The expression of GD2 on the surface of cancer cells is associated with neuroblastoma, melanoma, osteosarcoma, small cell lung cancer, among others.[19] When anti-GD2 directed antibodies were initially utilized in the treatment of melanoma or neuroblastoma significant dose limiting toxicities stemming from GD2 expression on peripheral nerves was noted.[20, 21] Despite the undesirable side effects, anti-GD2 therapeutic antibodies improved overall and progression free survival rates when given as a treatment with granulocyte macrophage-colony stimulating factor and interleukin-2.[5, 18] Clinical studies using revised anti-GD2 antibody treatments, such as humanization, chimerization, combination therapies, and Fc mutations, have

continued to observe acute, severe pain from treatment.[22-25] We propose anti-GD2 directed treatment would benefit from a requirement of co-expression of another marker, B7-H3, using the bispecific platform with tuned affinities. Importantly, B7-H3 expression is not found on nerves, which may minimize the pain toxicity associated with GD2-targeting therapies.[26] B7-H3 is considered an immune checkpoint molecule and pan-cancer antigen with a role in disease progression and metastasis.[27-29] Studies have found high B7-H3 expression in both melanoma and neuroblastoma patient populations that correlated with poor survival outcomes.[30-32] Considering the constraints associated with anti-GD2 targeting biologics, we suggest a novel approach centered around conditional B7-H3 expression. This could potentially revolutionize the therapeutic options available for patients targeted by these treatments.

Our study explored the potential of a bispecific antibody platform to increase the selectivity toward targeting cells expressing GD2 and B7-H3. Our innovative approach was validated through a series of cell binding and PET studies utilizing B78 melanoma cells with differential GD2/B7-H3 expression profiles. The results of these studies demonstrated that the GD2 and B7-H3 targeting bispecific antibodies selectively bind to cancer cells expressing both GD2 and B7-H3 with high avidity, showcasing their potential to precisely target tumor cells while sparing normal cells (i.e., peripheral nerves) expressing only GD2.

A similar dual-targeting approach using GD2 and B7-H3 was demonstrated using chimeric antigen targeting (CAR) T-cell therapy.[33] This platform may avert the limitations of other CAR-T cell therapies, such as limited accessibility for patients, complex manufacturing processes, and poor efficacy in solid tumors, and also requires the use of non-human transcription factors.[34] In comparison, we have found that the bispecific platform can be manufactured at scale and easily purified using traditional antibody purification techniques. The

improved selectivity demonstrated in this proof-of-concept study enables further investigations into potential therapies using this platform. Subsequent investigations may explore therapeutic avenues involving antibody-dependent cellular cytotoxicity, antibody-drug conjugates, or radioimmunotherapy. Using one or more of these therapeutic mechanisms of actions, a bispecific antibody requiring simultaneous expression of GD2 and B7-H3 may improve treatment outcomes and quality of life for patients of many cancer types.

The advancements we demonstrated for targeting GD2-positive tumors using a GD2 and B7-H3 targeting bispecific antibody has limitations. Our proof-of-concept study relied on engineering a murine melanoma cell line to establish differential B7-H3 and GD2 status. However, it should be acknowledged that species differences, such as receptor densities, necessitate evaluation using clinically relevant human cell lines or patient derived xenografts models. Additionally, we limited our study to using PET to demonstrate the enhanced selectivity toward cancers cells with our bispecific antibody strategy. It is imperative to assess whether the improved selectivity translates into improved treatment efficacy in subsequent studies. Furthermore, even though these studies here show minimal binding of bispecific antibodies to cells expressing GD2 in the absence of B7-H3, further studies evaluating actual binding of these bispecific antibodies (in comparison to dinutuximab) to nerves, and their relative induction of pain in vivo are still required. Additional validation of our findings that bispecific antibodies improve antibody selectivity should be extended to other tumors expressing GD2 and B7-H3. Analyses addressing these issues are beyond the scope of this manuscript, but several of these questions are addressed in a separate manuscript evaluating a novel anti-GD2/anti-B7-H3 bispecific antibody [35]. Following the necessary preclinical studies, the next generation

GD2/B7-H3 bispecific antibody holds promise to supersede existing anti-GD2 antibody therapies for cancer patients, ultimately improving treatment quality.

Conclusion

We designed a bispecific antibody to target GD2 and B7-H3 in a manner that requires co-expression on a single cell. By doing so, the selectivity of antibody binding was engineered toward GD2⁺/hB7-H3⁺ cells over GD2⁺/hB7-H3⁻ and resulting in high avidity, improving cancer cell targeting and potentially limiting side effects attributed to binding non targeted tissues such as nerves expressing GD2 only. Binding assays showed that INV34-6 displayed high avidity and selectivity to GD2⁺/hB7-H3⁺ over GD2⁺/hB7-H3⁻ B78 cells, whereas DINU bound similarly to both GD2 expressing cell lines. PET showed that the targeting improvements for INV34-6 over DINU or a non-specific control (bsAb CTRL) were retained *in vivo* using GD2⁺/hB7-H3⁺ and GD2⁺/hB7-H3⁻ B78 tumor models. Our results demonstrate that tuning the avidity toward antigens using bispecific antibodies is an effective strategy to improve selective targeting of cancer and may improve cancer therapies. PET was fundamental in showing that our antibody engineering approach translated into improved selectivity *in vivo*.

Question: Can a GD2 and B7-H3 targeting bispecific antibody be used to enhance the selectivity toward GD2 positive tumors?

Pertinent Findings: The bispecific antibody showed high avidity and selectivity toward tumors expressing GD2 and B7-H3.

Implications for patient care: Requiring dual expression of GD2 and B7-H3 using a bispecific antibody may provide a next-generation therapeutic approach to limit neuropathic pain caused by existing GD2 targeting antibodies.

Conflicts of Interest

This work was funded, in part, by Invenra Inc. Z.T.R. was previously employed by Invenra Inc and has an equity interest. Z.T.R., A.K.E., P.M.S., and R.H. received research funding from Invenra Inc. for research described in this manuscript.

Acknowledgments

This work was supported by the University of Wisconsin-Madison, the National Institutes of Health (R01HL153721, P01CA250972, R35CA197078, T32CA009206) and Department of Defense (Early Investigator Award, W81XWH1910285), The Wisconsin Alumni Research Foundation, Midwest Athletes Against Childhood Cancer; the University of Wisconsin Carbone Cancer Center and research grants from the Pablove Foundation, the HESI-thrive Foundation, the Hyundai Hope on Wheels Foundation, and the End Kids Cancer Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors wish to acknowledge the Small Animal Imaging and Radiotherapy Facility (SAIRF) at UW-Madison maintaining facilities for acquiring PET/CT, including support through the Cancer Center Support Grant NCI P30CA014520), and Invenra Inc. (Madison WI) for providing the bispecific mAbs used in this research.




Figure 1. A bispecific antibody platform that enables next generation targeting of tumors.

(a) Bispecific antibody construct with one arm containing a B7-H3 binding domain (α B7-H3), one arm containing a GD2 binding domain (α GD2), and an Fc containing the knob-in-hole (KiH) mutation (b) Bispecific antibody selectively targets $GD2^+/hB7-H3^+$ tumor cells with high bivalent avidity (upper panel) compared to low affinity monovalent binding to $GD2^+/hB7-H3^-$ nerve cells (bottom panel).




Figure 2. In vitro binding characterization of the avidity and selectivity for the bispecific GD2-B7-H3 targeting antibody. (a) INV34-6 showed selective binding to GD2⁺/hB7-H3⁺ B78 cells with high avidity compared to GD2⁺/hB7-H3⁻ B78 cells by flow cytometry. (b) Characterization of the binding properties for DINU using the differentially expressing GD2/hB7-H3 B78 cells showed high affinity to both GD2⁺ cell lines. Competition binding radioassays using (c) GD2⁺/hB7-H3⁻ B78 cells and (d) GD2⁺/hB7-H3⁺ B78 cells further demonstrated high avidity and selectivity of the bispecific GD2 and B7-H3 targeting platform.




Figure 3. *In vivo* PET shows bispecific antibody targeting GD2-B7-H3 has high avidity for GD2⁺/B7H3⁺ B78 tumors compared to nonspecific control. (a) Representative maximum intensity projection PET images showed high tumor uptake for [⁸⁹Zr]Zr-Df-INV34-6 compared to a non-specific control ([⁸⁹Zr]Zr-Df-bsAb CTRL) in a GD2⁺/hB7-H3⁺ B78 tumor model. Red arrows show tumor location. (b) Volume of interest analysis found significantly higher tumor uptake and comparable normal tissue uptake for [⁸⁹Zr]Zr-Df-INV34-6 following the initial imaging timepoint compared to [⁸⁹Zr]Zr-Df-bsAb CTRL (n=3). (c) *Ex vivo* biodistribution studies confirmed higher uptake of [⁸⁹Zr]Zr-Df-INV34-6 in the GD2⁺/hB7-H3⁺ B78 tumor model (n=3). p values (b-c) calculated using two-tailed Student's t-test at each timepoint (ns = non-significant, *p < 0.05, **p < 0.01, ***p < 0.001).




Figure 4. PET shows selectivity of GD2-B7H3 bispecific antibody *in vivo* compared to dinutuximab. Representative MIP PET images using radiolabeling [⁸⁹Zr]Zr-Df-INV34-6 showed increased uptake in B78 GD2⁺/hB7-H3⁺ tumors compared to GD2⁺/B7-H3⁻ B78 tumors. In comparison, tumor uptake of [⁸⁹Zr]Zr-Df-DINU in GD2⁺/hB7-H3⁻ B78 tumors and GD2⁺/hB7-H3⁺ B78 tumors was comparable. Red arrows indicate tumor location.




Figure 5. PET quantification of B78 tumor model with differential B7-H3 expression.

Volume of interest quantification of $[^{89}\text{Zr}]\text{Zr-Df-INV34-6}$ and $[^{89}\text{Zr}]\text{Zr-Df-DINU}$ in the (a) blood, (b) liver, (c) spleen, (d) kidney, (e) muscle, (f) bone, and (g) tumor at the imaging timepoints (%IA/cc) [n = 3-5]. (h) *Ex vivo* tumor uptake of $[^{89}\text{Zr}]\text{Zr-Df-INV34-6}$ and $[^{89}\text{Zr}]\text{Zr-Df-DINU}$ in GD2⁺/hB7-H3⁺ and GD2⁺/hB7-H3⁻ B78 tumors (n=3-5). Orange p values compare $[^{89}\text{Zr}]\text{Zr-Df-INV34-6}$ in GD2⁺/hB7-H3⁺ and GD2⁺/hB7-H3⁻ B78 tumors. p values were calculated using (g) two-tailed Student's t-test at each timepoint or (h) one-way ANOVA with Tukey's honest significant different post-hoc test (ns = non-significant at all timepoints, *p < 0.05. ***p < 0.001).

References

1. Nazha B, Inal C, Owonikoko TK. Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy. *Frontiers in Oncology*. 2020;10. doi:10.3389/fonc.2020.01000.
2. Handgretinger R, Anderson K, Lang P, Dopfer R, Klingebiel T, Schrappe M, et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. *European Journal of Cancer*. 1995;31:261-7. doi:[https://doi.org/10.1016/0959-8049\(94\)00413-Y](https://doi.org/10.1016/0959-8049(94)00413-Y).
3. Albertini MR, Hank JA, Schiller JH, Khorsand M, Borchert AA, Gan J, et al. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 1997;3:1277-88.
4. McGinty L, Kolesar J. Dinutuximab for maintenance therapy in pediatric neuroblastoma. *American Journal of Health-System Pharmacy*. 2017;74:563-7. doi:10.2146/ajhp160228.
5. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma. *New England Journal of Medicine*. 2010;363:1324-34. doi:10.1056/NEJMoa0911123.
6. Ahmed M, Cheung N-KV. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. *FEBS Letters*. 2014;588:288-97. doi:<https://doi.org/10.1016/j.febslet.2013.11.030>.
7. Zhou W-T, Jin W-L. B7-H3/CD276: An Emerging Cancer Immunotherapy. *Frontiers in Immunology*. 2021;12. doi:10.3389/fimmu.2021.701006.
8. Modak S, Kramer K, Gultekin SH, Guo HF, Cheung N-KV. Monoclonal Antibody 8H9 Targets a Novel Cell Surface Antigen Expressed by a Wide Spectrum of Human Solid Tumors. *Cancer Research*. 2001;61:4048-54.
9. Maachani UB, Tosi U, Pisapia DJ, Mukherjee S, Marnell CS, Voronina J, et al. B7-H3 as a Prognostic Biomarker and Therapeutic Target in Pediatric central nervous system Tumors. *Translational Oncology*. 2020;13:365-71. doi:<https://doi.org/10.1016/j.tranon.2019.11.006>.
10. Powderly J, Cote G, Flaherty K, Szmulewitz RZ, Ribas A, Weber J, et al. Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3. *Journal for ImmunoTherapy of Cancer*. 2015;3:O8. doi:10.1186/2051-1426-3-s2-o8.
11. Tang X, Liu F, Liu Z, Cao Y, Zhang Z, Wang Y, et al. Bioactivity and safety of B7-H3-targeted chimeric antigen receptor T cells against anaplastic meningioma. *Clinical & Translational Immunology*. 2020;9:e1137. doi:<https://doi.org/10.1002/cti2.1137>.
12. Lu R-M, Hwang Y-C, Liu IJ, Lee C-C, Tsai H-Z, Li H-J, et al. Development of therapeutic antibodies for the treatment of diseases. *Journal of Biomedical Science*. 2020;27:1. doi:10.1186/s12929-019-0592-z.
13. Brinkmann U, Kontermann RE. The making of bispecific antibodies. *MAbs*. 2017;9:182-212. doi:10.1080/19420862.2016.1268307.
14. Labrijn AF, Janmaat ML, Reichert JM, Parren P. Bispecific antibodies: a mechanistic review of the pipeline. *Nat Rev Drug Discov*. 2019;18:585-608. doi:10.1038/s41573-019-0028-1.

15. Xu Y, Lee J, Tran C, Heibeck TH, Wang WD, Yang J, et al. Production of bispecific antibodies in "knobs-into-holes" using a cell-free expression system. *MAbs*. 2015;7:231-42. doi:10.4161/19420862.2015.989013.
16. Ridgway JBB, Presta LG, Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. *Protein Engineering, Design and Selection*. 1996;9:617-21. doi:10.1093/protein/9.7.617.
17. Klein C, Brinkmann U, Reichert JM, Kontermann RE. The present and future of bispecific antibodies for cancer therapy. *Nature Reviews Drug Discovery*. 2024. doi:10.1038/s41573-024-00896-6.
18. Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, et al. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2021;27:2179-89. doi:10.1158/1078-0432.Ccr-20-3909.
19. Dobrenkov K, Cheung N-KV. GD2-Targeted Immunotherapy and Radioimmunotherapy. *Seminars in Oncology*. 2014;41:589-612. doi:<https://doi.org/10.1053/j.seminoncol.2014.07.003>.
20. Cheung NK, Lazarus H, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. *J Clin Oncol*. 1987;5:1430-40. doi:10.1200/jco.1987.5.9.1430.
21. Cheung NV, Lazarus H, Miraldi FD, Berger NA, Abramowsky CR, Saarinen UM, et al. Reassessment of patient response to monoclonal antibody 3F8. *Journal of Clinical Oncology*. 1992;10:671-2. doi:10.1200/jco.1992.10.4.671.
22. Saleh MN, Khazaeli MB, Wheeler RH, Allen L, Tilden AB, Grizzle W, et al. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. *Hum Antibodies Hybridomas*. 1992;3:19-24.
23. Murray JL, Kleinerman ES, Jia S-F, Rosenblum MG, Eton O, Buzaid A, et al. Phase Ia/Ib Trial of Anti-GD2 Chimeric Monoclonal Antibody 14.18 (ch 14.18) and Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (rhGM-CSF) in Metastatic Melanoma. *Journal of Immunotherapy*. 1996;19:206-17.
24. Navid F, Sondel PM, Barfield R, Shulkin BL, Kaufman RA, Allay JA, et al. Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. *J Clin Oncol*. 2014;32:1445-52. doi:10.1200/jco.2013.50.4423.
25. Kushner BH, Kramer K, Modak S, Cheung N-KV. Successful Multifold Dose Escalation of Anti-GD2 Monoclonal Antibody 3F8 in Patients With Neuroblastoma: A Phase I Study. *Journal of Clinical Oncology*. 2011;29:1168-74. doi:10.1200/jco.2010.28.3317.
26. Castriconi R, Dondero A, Augugliaro R, Cantoni C, Carnemolla B, Sementa AR, et al. Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. *Proc Natl Acad Sci U S A*. 2004;101:12640-5. doi:10.1073/pnas.0405025101.
27. Yang S, Wei W, Zhao Q. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy. *International Journal of Biological Sciences*. 2020;16:1767-73. doi:10.7150/ijbs.41105.
28. Dong P, Xiong Y, Yue J, Hanley SJB, Watari H. B7H3 As a Promoter of Metastasis and Promising Therapeutic Target. *Frontiers in Oncology*. 2018;8. doi:10.3389/fonc.2018.00264.

29. Seaman S, Zhu Z, Saha S, Zhang XM, Yang MY, Hilton MB, et al. Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature. *Cancer Cell*. 2017;31:501-15.e8. doi:<https://doi.org/10.1016/j.ccell.2017.03.005>.
30. Wang J, Chong KK, Nakamura Y, Nguyen L, Huang SK, Kuo C, et al. B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma. *J Invest Dermatol*. 2013;133:2050-8. doi:10.1038/jid.2013.114.
31. Loo D, Alderson RF, Chen FZ, Huang L, Zhang W, Gorlatov S, et al. Development of an Fc-Enhanced Anti-B7-H3 Monoclonal Antibody with Potent Antitumor Activity. *Clinical Cancer Research*. 2012;18:3834-45. doi:10.1158/1078-0432.Ccr-12-0715.
32. Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, et al. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. *Clinical Cancer Research*. 2019;25:2560-74. doi:10.1158/1078-0432.Ccr-18-0432.
33. Moghimi B, Muthugounder S, Jambon S, Tibbetts R, Hung L, Bassiri H, et al. Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. *Nature Communications*. 2021;12:511. doi:10.1038/s41467-020-20785-x.
34. Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. *Blood Cancer Journal*. 2021;11:69. doi:10.1038/s41408-021-00459-7.
35. Erbe AK, Feils AS, Hampton A, Rosenkrans ZT, Felder M, Wiwczar J, et al. Bispecific GD2 x B7-H3 Antibody Improves Tumor Targeting and Reduces Toxicity while Maintaining Efficacy for Neuroblastoma. *bioRxiv*. 2024:2024.05.23.595588. doi:10.1101/2024.05.23.595588.

Graphical Abstract

